Literature DB >> 22930214

Laparoscopic sacrocolpopexy versus transvaginal mesh for recurrent pelvic organ prolapse.

Cheryl B Iglesia1, Douglass S Hale, Vincent R Lucente.   

Abstract

Both expert surgeons agree with the following: (1) Surgical mesh, whether placed laparoscopically or transvaginally, is indicated for pelvic floor reconstruction in cases involving recurrent advanced pelvic organ prolapse. (2) Procedural expertise and experience gained from performing a high volume of cases is fundamentally necessary. Knowledge of outcomes and complications from an individual surgeon's audit of cases is also needed when discussing the risks and benefits of procedures and alternatives. Yet controversy still exists on how best to teach new surgical techniques and optimal ways to efficiently track outcomes, including subjective and objective cure of prolapse as well as perioperative complications. A mesh registry will be useful in providing data needed for surgeons. Cost factors are also a consideration since laparoscopic and especially robotic surgical mesh procedures are generally more costly than transvaginal mesh kits when operative time, extra instrumentation and length of stay are included. Long-term outcomes, particularly for transvaginal mesh procedures, are lacking. In conclusion, all surgery poses risks; however, patients should be made aware of the pros and cons of various routes of surgery as well as the potential risks and benefits of using mesh. Surgeons should provide patients with honest information about their own experience implanting mesh and also their experience dealing with mesh-related complications.

Entities:  

Mesh:

Year:  2012        PMID: 22930214     DOI: 10.1007/s00192-012-1918-5

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  31 in total

Review 1.  Abdominal, laparoscopic, and robotic surgery for pelvic organ prolapse.

Authors:  Colleen D McDermott; Douglass S Hale
Journal:  Obstet Gynecol Clin North Am       Date:  2009-09       Impact factor: 2.844

2.  Selection of patients in whom vaginal graft use may be appropriate. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery.

Authors:  G Willy Davila; Kaven Baessler; Michel Cosson; Linda Cardozo
Journal:  Int Urogynecol J       Date:  2012-03-07       Impact factor: 2.894

3.  Laparoscopic sacral colpopexy for vaginal vault prolapse.

Authors:  C H Nezhat; F Nezhat; C Nezhat
Journal:  Obstet Gynecol       Date:  1994-11       Impact factor: 7.661

4.  Long-term results of the tension-free vaginal tape (TVT) procedure for surgical treatment of female stress urinary incontinence.

Authors:  C G Nilsson; N Kuuva; C Falconer; M Rezapour; U Ulmsten
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2001

5.  Trocar-guided mesh compared with conventional vaginal repair in recurrent prolapse: a randomized controlled trial.

Authors:  Mariëlla I Withagen; Alfredo L Milani; Jan den Boon; Harry A Vervest; Mark E Vierhout
Journal:  Obstet Gynecol       Date:  2011-02       Impact factor: 7.661

6.  Vaginal versus abdominal reconstructive surgery for the treatment of pelvic support defects: a prospective randomized study with long-term outcome evaluation.

Authors:  J T Benson; V Lucente; E McClellan
Journal:  Am J Obstet Gynecol       Date:  1996-12       Impact factor: 8.661

7.  Laparoscopic compared with robotic sacrocolpopexy for vaginal prolapse: a randomized controlled trial.

Authors:  Marie Fidela R Paraiso; J Eric Jelovsek; Anna Frick; Chi Chung Grace Chen; Matthew D Barber
Journal:  Obstet Gynecol       Date:  2011-11       Impact factor: 7.661

8.  Incidence of and risk factors for pulmonary complications after nonthoracic surgery.

Authors:  Finlay A McAlister; Kimberly Bertsch; Jeremy Man; John Bradley; Michael Jacka
Journal:  Am J Respir Crit Care Med       Date:  2004-11-24       Impact factor: 21.405

9.  Risk factors for the recurrence of pelvic organ prolapse after vaginal surgery: a review at 5 years after surgery.

Authors:  I Diez-Itza; I Aizpitarte; A Becerro
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-02-28

Review 10.  Abdominal sacrocolpopexy: a comprehensive review.

Authors:  Ingrid E Nygaard; Rebecca McCreery; Linda Brubaker; AnnaMarie Connolly; Geoff Cundiff; Anne M Weber; Halina Zyczynski
Journal:  Obstet Gynecol       Date:  2004-10       Impact factor: 7.661

View more
  6 in total

1.  The challenge of implementing laparoscopic sacrocolpopexy.

Authors:  Jan Deprest; Ladislav Krofta; Frank Van der Aa; Alfredo L Milani; Jan Den Boon; Filip Claerhout; Jan-Paul Roovers
Journal:  Int Urogynecol J       Date:  2014-05-21       Impact factor: 2.894

Review 2.  Recurrent pelvic organ prolapse: International Urogynecological Association Research and Development Committee opinion.

Authors:  Sharif Ismail; Jonathan Duckett; Diaa Rizk; Olanrewaju Sorinola; Dorothy Kammerer-Doak; Oscar Contreras-Ortiz; Hazem Al-Mandeel; Kamil Svabik; Mitesh Parekh; Christian Phillips
Journal:  Int Urogynecol J       Date:  2016-07-05       Impact factor: 2.894

3.  Procedure Choice in Primary Versus Recurrent Prolapse: A Study of Fellowship-Trained Surgeons.

Authors:  Rachel High; Alex Kavanagh; Rose Khavari; Julie Stewart; Danielle D Antosh
Journal:  Female Pelvic Med Reconstr Surg       Date:  2018 Jul/Aug       Impact factor: 2.091

Review 4.  Outcomes of robotic sacrocolpopexy: a systematic review and meta-analysis.

Authors:  Catherine O Hudson; Gina M Northington; Robert H Lyles; Deborah R Karp
Journal:  Female Pelvic Med Reconstr Surg       Date:  2014 Sep-Oct       Impact factor: 2.091

5.  LeFort colpocleisis for recurrent pelvic organ prolapse.

Authors:  Xiaojuan Wang; Changdong Hu; Yisong Chen; Keqin Hua
Journal:  Int Urogynecol J       Date:  2019-05-08       Impact factor: 2.894

Review 6.  Indications, contraindications, and complications of mesh in surgical treatment of pelvic organ prolapse.

Authors:  David R Ellington; Holly E Richter
Journal:  Clin Obstet Gynecol       Date:  2013-06       Impact factor: 2.190

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.